# A Study for the Neoadjuvant Treatment of Breast Cancer

> **NCT05420454** · PHASE4 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 1576 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05420454
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-10
- **Primary completion:** 2027-06-10
- **Final completion:** 2027-12-20
- **Target enrollment:** 1576 (ESTIMATED)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420454, "A Study for the Neoadjuvant Treatment of Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05420454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*